



# Erratum: Anti-metastatic Properties of Naproxen-HBTA in a Murine Model of Cutaneous Melanoma

Frontiers Pharmacology Editorial Office\*

melanoma, target-therapy, apoptosis

Pharmacology Editorial Office, Frontiers Media SA, Lausanne, Switzerland

# **OPEN ACCESS**

# Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

### \*Correspondence:

Frontiers Pharmacology Editorial Office pharmacology.editorial.office@ frontiersin.org

# Specialty section:

This article was submitted to Pharmacology of Anti-Cancer Drugs, a section of the journal Frontiers in Pharmacology

> Received: 20 February 2019 Accepted: 20 February 2019 Published: 26 February 2019

# Citatior

Frontiers Pharmacology Editorial
Office (2019) Erratum: Anti-metastatic
Properties of Naproxen-HBTA in a
Murine Model of Cutaneous
Melanoma. Front. Pharmacol. 10:213.
doi: 10.3389/fphar.2019.00213

# An Erratum on

Anti-metastatic Properties of Naproxen-HBTA in a Murine Model of Cutaneous Melanoma Ercolano, G., De Cicco, P., Frecentese, F., Saccone, I., Corvino, A., Giordano, F., et al. (2019). Front. Pharmacol. 10:66. doi: 10.3389/fphar.2019.00066

Keywords: cyclooxygenases (COXs), hydrogen sulfide (H2S), non-steroidal anti-inflammatory drugs (NSAIDs),

The statement declaring the relationship between the handling editor and two of the authors has been clarified for transparency of the process. The updated statement should read, in full:

After the conclusion of the peer review, the handling editor noticed and declared a collaboration and shared affiliation with two of the authors, VaC and ViC. These authors provided an additional analysis requested by a reviewer during review. They were later added as co-authors and identified to the editor after the provisional acceptance of the manuscript. Under these exceptional circumstances, the relationship did not affect the objectivity of the review process, and this situation is being declared for transparency.

The publisher apologizes for this oversight. The original article has been updated.

1

Copyright © 2019 Frontiers Pharmacology Editorial Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.